FridaySep 09, 2022 12:04 pm

Study Finds That Using Headgear May Reduce Concussion Risk in Lacrosse Players

Despite lacrosse being a noncontact sport, head impacts and incidental concussions are common occurrences during games. The noncontact sports rules also seep into the mandated protective equipment allowed for girls’ lacrosse, which is limited to eyewear and mouthguards. Girls’ lacrosse has increasingly grown in popularity this past decade, with figures showing that prior to the pandemic, its adoption in America grew by more than 50%. While the use of soft-shell headgear has been permitted in the game since 2017, using headgear is still a bone of contention in a number of states. Critics have even argued that the use of…

Continue Reading

FridaySep 09, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumors Glioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cure CNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, Berubicin Berubicin is an anthracycline (chemotherapy agent) with the apparent ability to cross the blood-brain barrier to attack central nervous system tumors, which grants it a unique status among anthracyclines CNS has shown evidence…

Continue Reading

ThursdaySep 08, 2022 12:10 pm

Researchers Find Link Between Steroidal Allergy Treatments, Decreased Brain Function

Pharmaceutical medications may have allowed us to beat innumerable diseases and significantly increase our lifetimes, but they are not without risk. One chief complaint about most pharmaceuticals is that while they are often effective at mitigating the diseases they are deployed against, they often cause unwanted side effects. These side effects can range from drowsiness, dry mouth, and skin rashes to severe, life-threatening side effects. According to a previous study by the Federal Agency for Healthcare Research and Quality, an estimated 4.5 million patients visit emergency rooms or doctors’ offices each year due to adverse drug effects. Building on the…

Continue Reading

WednesdaySep 07, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage

Medical company Odyssey Health has received approval from the Safety Review Committee to start Cohort II of its Phase I trial’s Multiday Ascending Dosing (“MAD”) stage The approval follows evidence that Odyssey’s PRV-002 concussion drug candidate was safe and well-tolerated, as seen in Cohort I of the MAD stage The pharmacokinetic analysis also supports the hypothesis that more drug is getting to the brain itself, backing the company’s use of its patent-pending breath-propelled intranasal drug administration device The company believes that the intranasal drug/delivery combination will be instrumental in the success of the PRV-002 drug candidate in planned Phase II/III…

Continue Reading

WednesdaySep 07, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin

CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 million The company closed the quarter with $9.0 million in cash, and a working capital of approximately $10.3 million which, it is confident, will fund its operations into the 2023 calendar year CNS looks to continue site initiations across the U.S., Italy, France, Spain, and Switzerland, while also pushing for regulatory and ethics…

Continue Reading

WednesdaySep 07, 2022 9:44 am

Accessibility Issues Prevent Individuals in Rural Areas from Undergoing Lifesaving Tumor Treatment

Tumors remain one of the deadliest diseases in the world, accounting for around one in six deaths globally in 2020. While scientists may not have found a cure for life-threatening tumors despite decades of research, there are a variety of treatments that can reduce and even eliminate tumors. However, people who live in rural areas have limited access to cancer treatments that could save their lives, highlighting a startling inequality in access to lifesaving cancer treatments. For starters, some cancer patients have had their tumors completely eradicated after undergoing Chimeric antigen receptor T-cell (CAR T-cell) therapy. However, patients who reside…

Continue Reading

TuesdaySep 06, 2022 11:22 am

Research Indicates Better Sleep Efficiency Benefits Fibromyalgia Sufferers

New research has found that improved sleep efficiency in patients who suffer from fibromyalgia and insomnia may improve their pain-related disorder. Fibromyalgia is a condition characterized by extensive musculoskeletal pain and tenderness, which is often accompanied by fatigue, mood and memory as well as sleep issues. The disorder is often caused by stressful events, which may include emotional, psychological or physical stress. Injuries or viral infections may also cause this pain disorder. On the other hand, insomnia is a sleep disorder that makes it hard for individuals to fall asleep or stay asleep. This common disorder may also cause individuals…

Continue Reading

FridaySep 02, 2022 10:09 am

Study Highlights Need for Postnatal Depression Screening

Researchers at the University of Queensland have highlighted the need to screen for perinatal depression for women during the pregnancy period, after learning that women suffering from persistent depression have a heightened risk of developing the condition. Perinatal depression includes symptoms of depression, stress and anxiety that women sometimes experience from conception to a year following infant birth. The study’s objective was to assess the prevalence, timing of onset and duration of depression symptoms in the perinatal period in women with depression. The study involved more than 7,000 participants who were divided into two subgroups: women who had previously been…

Continue Reading

ThursdaySep 01, 2022 10:58 am

Research Suggests Some 50% of Cancers Result from Preventable Factors

Cancer is said to be the second-leading cause of death globally, following heart disease. Among the different types of cancer, lung cancer is the leading cause of cancer death, followed by colorectal and liver cancers. A new study suggests that roughly 44% of the deaths caused by cancer can be attributed to risk factors that are preventable. These factors include drinking too much alcohol, smoking and having a high BMI. The researchers were focused on analyzing the relationship between cancer and various risk factors, using data obtained from the Global Burden of Disease project by the Institute for Health Metrics…

Continue Reading

ThursdaySep 01, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research

When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”) So far, CNS has received FDA Fast Track Designation on its Berubicin clinical study, inching the company closer to offering a viable solution to the millions of people dealing with GBM, a devastating malignant brain cancer It remains committed to pushing the envelope in terms of research and development of potential GBM treatment, as we ll as brain cancers in general, to offer a viable solution to…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000